证券代码：300832 证券简称：新产业 公告编号：2025-044 深圳市新产业生物医学工程股份有限公司 关于控股股东部分质押股份办理延期购回手续的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于近日收到 公司控股股东西藏新产业投资管理有限公司（以下简称"西藏新产业"）的函告， 获悉西藏新产业所持有的公司 622 万股（含补充质押 97 万股）质押股份办理了 延期购回手续。具体事项如下： 注：上表中数值若出现总数与各分项数值之和尾数不符，均为四舍五入原因所致。 上述办理延期购回手续的质押股份相关情况请参见公司分别于 2023 年 6 月 1 日、2024 年 5 月 14 日、2025 年 4 月 10 日在巨潮资讯网披露的《关于控股股 东部分股份办理质押及实际控制人部分股份解除质押的公告》（公告编号： 2023-062）、《关于控股股东部分质押股份解除质押及办理延期购回手续的公告》 （公告编号：2024-041）、《关于控股股东部分股份办理补充质押的公告》（公 1 股东 名称 是否为 控股股 ...

Core Insights - The "Technology-Finance-Industry" virtuous cycle is progressing, with the Strategic Emerging Industry Index reaching 187.63 points in Q3 2024, a 2.69% increase from the end of 2023, indicating a stable upward trend [1][2] Group 1: Index Performance - The index shows steady improvement, with all four sub-indices rising, particularly the Financial Development Index, which increased by 2.01% due to stable growth in bank loans [2][4] - By the end of September 2024, medium to long-term loans for high-tech manufacturing reached 2.9 trillion yuan, and loans for "specialized, refined, and innovative" enterprises reached 4.3 trillion yuan, with year-on-year growth of 12% and 13.5% respectively [4] - The Environmental Support Index grew by 3.50%, reflecting stable growth in financial, innovation, and industrial environments, with a 14.89% increase in the scale of science and technology innovation theme funds [4] Group 2: Innovation and Industry Performance - The Innovation Index increased by 3.52%, although innovation output indicators lagged due to reduced R&D investment and stricter national standards [5] - The Industry Effectiveness Index rose by 2.36%, but this represents a significant decline from the previous annual compound growth rate of 16.16% from 2019 to 2023 [6] - The new energy vehicle and new generation information technology industries led in performance, growing by 4.33% and 2.81% respectively, while the new energy industry saw a decline of 0.36% [6][11] Group 3: Sector-Specific Insights - The new energy vehicle sector experienced a historic turning point in July 2024, with monthly retail sales of new energy passenger vehicles surpassing traditional fuel vehicles [8] - The biotechnology sector showed a recovery with a growth rate of 2.55%, driven by active merger and acquisition activities [10] - The new materials sector's growth was minimal at 0.47%, with a slight increase in enterprise numbers but a decrease in total tax revenue [10]

《中共中央关于进一步全面深化改革、推进中国式现代化的决定》提出，壮大县域富民产业，构建多元 化食物供给体系，培育乡村新产业新业态。如何用好乡村资源、发展新产业新业态成为热门话题。 乡村产业并非新鲜事物，但乡村新产业新业态是近些年才出现的。乡村新产业新业态的新，不仅体现在 领域和业态上，更体现在产业链条、融合层次和技术水平上。以往，不少地方乡村产业多集中在周期 短、门槛低的传统种养业，形不成链条，打不开市场。乡村新产业新业态则强调全环节提升、全链条增 值、全产业融合。一般认为，其包括农村一二三产业融合、农产品加工业、乡村休闲旅游、农村创新创 业等，特点是依托创新打破传统产业边界和业态模式。 从基层情况看，乡村产业发展面临不少困难。一是要素活力不足。农村资源变资产的渠道尚未完全打 通，阻碍了资本进入乡村产业。新产业新业态发展用地供给不足，产业融合发展项目用地矛盾较突出。 农村缺人才，而城市人才服务乡村产业的激励保障机制还不健全。二是质量效益不高。有的地方创新能 力不够强，特别是农产品加工创新不足，休闲旅游存在同质化现象。产业融合层次低，乡村价值功能开 发不充分。三是产业基础设施仍然薄弱。一些农村供水、供电、供气条 ...

在当下中国经济新旧动能转换的关键时期，产业格局正经历深刻变革，新产业（300832）蓬勃兴起，传 统产业加速升级。然而，"内卷式"竞争这一顽疾却在部分行业悄然滋生。部分光伏、储能等领域企业为 争夺市场份额，不惜低价倾销，扰乱市场秩序。多位受访的业内人士对记者表示，"内卷式"竞争的深层 次原因主要是技术创新不足、专利保护缺失、市场信号不清等。面对这一困境，国家发改委、国家市场 监管总局等多部门密集出台整治举措，力求斩断"内卷"枷锁。与此同时，业内头部企业纷纷探索破局之 道，以模式创新、技术革新及强化专利保护为利刃，在激烈竞争中开辟差异化发展路径，引领行业 从"价格内卷"向"价值创造"转型。(中国证券报) ...

Group 1 - The core viewpoint of the articles highlights the strategic partnership between Chaoxi Times (Yaoling Shandong) and Skyworth Photovoltaic, aimed at developing and promoting distributed photovoltaic projects for residential and commercial use, enhancing the application of Chaoxi Times' photovoltaic products in the market [1][2] - The collaboration is seen as a significant achievement in attracting investment to Linyi City, focusing on practical, quality, and rapid development [1] - The local government expresses strong support for the partnership, emphasizing innovation, quality, and social responsibility as key drivers for future growth [1] Group 2 - Chaoxi Times (Shandong) has over 100 patents in the field of new green power generation materials, with high transparency glass achieving a light transmittance of 99.16% and ultra-low reflectance below 2% [2] - The company's BIPV (Building Integrated Photovoltaics) components have a photoelectric conversion rate exceeding 20%, with energy consumption reduced by 20% and carbon emissions decreased by 30%, while production costs are lowered by 30% and efficiency increased by 15% [2] - The company aims to redefine the value of green industrial buildings through technology, positioning itself as a leader in clean energy solutions [2]

证券代码：300832 证券简称：新产业 公告编号：2025-043 深圳市新产业生物医学工程股份有限公司 关于获得医疗器械注册证的公告 雄烯二酮（Androstenedione）是一种重要的内源性类固醇激素，属于雄激素 的一员，主要由肾上腺及性腺（女性的卵巢或男性的睾丸）产生。由于雄烯二酮 1 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，深圳市新产业生物医学工程股份有限公司（以下简称"公司"）收到 了广东省药品监督管理局颁发的 3 项《医疗器械注册证》。具体情况如下： | 序 | 产品名称 | 注册 | 注册证编号 | | | 注册证有效期 | | | | | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | | 分类 | | | | | | | | | | | | | | | | | | | | | | 本试剂盒用于体外定量测 定人血清或血浆中雄烯二 | | | 雄烯二酮测定试 | | 粤械注准 | 2025 | 年 | 0 ...

Group 1 - The number of companies in strategic emerging industries listed on the Shanghai and Shenzhen stock exchanges is approaching 2,700, accounting for over 40% of the market capitalization [1] - More than 90% of new listings on the Sci-Tech Innovation Board, Growth Enterprise Market, and Beijing Stock Exchange in 2024 will belong to strategic emerging industries or high-tech enterprises [1] - The conditions for technology companies to go public have become more accommodating, with multiple listing paths established for unprofitable companies, red-chip companies, and those with special voting rights [1] Group 2 - Since the introduction of the "merger and acquisition six guidelines," listed companies have actively planned mergers and acquisitions, resulting in over 1,400 disclosed asset restructurings, a year-on-year increase of over 40% [1] - The number of major asset restructurings has exceeded 170, showing a year-on-year increase of over 220% [1] - Approximately 650 asset restructurings have been disclosed by companies in strategic emerging industries, with over 80 being major restructurings [1] Group 3 - Since the implementation of the registration system reform, 90% of companies listed on the Sci-Tech Innovation Board and Beijing Stock Exchange, and over half of those on the Growth Enterprise Market, have received investments from private equity and venture capital funds [2] - The scale and proportion of investments from private equity and venture capital funds in strategic emerging industries continue to rise, with over 100,000 projects currently funded and total investment exceeding 4 trillion yuan [2] - The bond market has become an important channel for direct financing for technology companies, with cumulative issuance of Sci-Tech bonds reaching 1.2 trillion yuan [2] Group 4 - In 2024, 539 Sci-Tech bonds were issued, with a total issuance scale of 610 billion yuan, representing a year-on-year increase of 64% [2] - The funds raised are primarily directed towards cutting-edge fields such as semiconductors, artificial intelligence, new energy, and high-end manufacturing [2]

Core Insights - XCMG Group has successfully hosted the International Customer Festival for seven consecutive years, which serves as a global marketing accelerator and a foundation for advanced manufacturing in Xuzhou [1][2] - The company has achieved over 100 billion yuan in operating scale for five consecutive years, with international revenue accounting for more than 46% [2] - XCMG Group aims to double its scale to over 200 billion yuan by 2030, with international revenue expected to exceed 60% [2] Group 1 - The International Customer Festival attracted over 2,000 guests from more than 80 countries, showcasing XCMG's advantages in the engineering machinery industry [1] - XCMG's product range includes construction machinery, commercial vehicles, mining machinery, agricultural machinery, sanitation equipment, emergency rescue gear, and core components [1] - The company focuses on a "5+1" industrial layout, strengthening its core engineering machinery sector while developing strategic new industries and upgrading modern services [1] Group 2 - XCMG has established a global operational system of "1+14+N," with R&D centers in countries such as Germany, the USA, Australia, and Brazil [2] - The company has developed a range of green and intelligent products, including the world's largest hybrid all-terrain crane and fully electric loaders [2] - XCMG's future strategy emphasizes transitioning from a traditional manufacturing company to a solution-oriented service provider, enhancing global integration and operational efficiency [2]

证券代码：300832 证券简称：新产业 公告编号：2025-042 深圳市新产业生物医学工程股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）2024 年年 度权益分派方案已获 2025 年 5 月 19 日召开的 2024 年年度股东会审议通过，现 将权益分派具体实施事宜公告如下： 一、 股东会审议通过的权益分配方案情况 1. 2024 年年度股东会审议通过的分配方案为：以 2024 年年度权益分派实 施公告中确定的股权登记日下午收市时的总股本为基数，按每股分配现金红利金 额不变的原则，向全体股东每 10 股派发现金红利 13 元（含税），不送红股，不 以资本公积金转增股本。 2. 本次实施的权益分派方案与 2024 年年度股东会审议通过的分配方案及 其调整原则一致。 3. 本次实施的权益分派方案距离股东会审议通过时间未超过两个月。 二、 本次实施的权益分派方案 本公司 2024 年年度权益分派方案为：以公司现有总股本 785,718,785 股为基 数， ...

Group 1 - The core viewpoint of the news is the performance and structure of the China Europe CSI All-Share Healthcare Equipment and Services Index Fund A, which has experienced a slight decline recently [1] - As of May 19, the fund's latest net value is 1.05 yuan, marking a continuous drop for four trading days with a cumulative decline of 1.26% [1] - The fund was established in August 2024 with a total size of 0.13 billion yuan and has achieved a cumulative return of 4.82% since inception [1] Group 2 - The fund's holder structure shows that institutional investors hold 0.10 billion shares, accounting for 91.94% of the total shares, while individual investors hold 0.01 billion shares, making up 8.06% [1] - As of March 31, 2025, the top ten holdings of the fund account for a total of 41.48%, with major investments in companies such as Mindray Medical (9.10%), Aier Eye Hospital (7.77%), and United Imaging Healthcare (6.36%) [3]